Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTC857 relative oral bioavailability crossover study in healthy adults
NL-OMON50852Phase 1Active, not recruiting
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of utreloxastat in Parkinson's disease (PD), sponsored by PTC Therapeutics, Inc. Primary endpoint: Relative bioavailability of PTC857. Started Jun 2021; status: active, not recruiting.
02
Drugs
utreloxastat
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON50852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50852.